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Context: NACHT leucine-rich-repeat protein 5 (NALP5)/maternal antigen that embryo requires
(MATER) is an autoantigen in hypoparathyroidism associated with autoimmune polyendocrine
syndrome type 1 (APS1) but is also expressed in the ovary.Mater is an autoantigen in experimental
autoimmune oophoritis.
Objectives: The objectives of the study were to determine the frequency of NALP5/MATER auto-
antibodies (NALP5/MATER-Ab) in women with premature ovarian insufficiency (POI) and in pa-
tients with autoimmune Addison’s disease (AAD) and to evaluate whether inhibin chains are a
target for autoantibodies in POI.
Methods: Autoantibodies against NALP5/MATER and inhibin chains- and -A were determined
by radiobinding assays in 172 patients with AADwithout clinical signs of gonadal insufficiency, 41
women with both AAD and autoimmune POI [steroidogenic cell autoimmune POI (SCA-POI)], 119
women with idiopathic POI, 19 patients with APS1, and 211 healthy control subjects.
Results:NALP5/MATER-Abwere detected in 11of 19 (58%) sera fromAPS1patients, 12 of 172 (7%)
AAD sera, 5 of 41 (12%) SCA-POI sera, 0 of 119 idiopathic POI sera and 1 of 211 healthy control sera
(P .001). None of 160 POI sera, including 41 sera fromwomenwith SCA-POI and 119womenwith
idiopathic POI, and none of 211 healthy control sera were positive for inhibin chain-/A
autoantibodies.
Conclusions: NALP5/MATER-Ab are associated with hypoparathyroidism in APS1 but are present
also in patientswithAADand inwomenwith SCA-POIwithout hypoparathyroidism. Inhibin chains
do not appear to be likely candidate targets of autoantibodies in human POI. (J Clin Endocrinol
Metab 100: 1941–1948, 2015)
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Autoimmune Addison’s disease (AAD) is the conse-quence of the autoimmune destruction of adreno-
cortical cells, with subsequent deficit of glucocorticoids
and mineralcorticoids and a life-long need for a substitu-
tive therapy (1, 2). The adrenal autoimmune reaction is
accompanied by the production of 21-hydroxylase auto-
antibodies (21OHAb), themajor immunemarker of AAD
(3–7).
AAD is frequently associated with other endocrine and
nonendocrine autoimmune (or immunomediated) dis-
eases, in the so-called autoimmune polyendocrine syn-
dromes (APS) (5, 8). Although APS type 2 is polygenic,
with a major contribution of the HLA genes, APS type 1
(APS1) is amonogenic disorder causedbymutations in the
autoimmune regulator (aire) gene on chromosome 21 (5,
9–13). The serum from patients with APS1 expresses au-
toantibodies directed against several targets (14–19).
Immunoscreening of a human parathyroid cDNA li-
brary identified NACHT leucine-rich-repeat protein 5
(NALP5) as a novel autoantigen, target of autoantibodies,
associated with hypoparathyroidism in APS1 patients
(20). NALP5 is a 1200-amino acid-long protein also de-
nominated maternal antigen that embryo requires (MA-
TER) or NLRP5 (21). Interestingly, NALP5/MATER is
predominantly expressed in parathyroid tissue but also in
the ovaries, although to a lesser extent (20). Because bio-
chemical and clinical signs of ovarian autoimmunity are
frequently present in women with APS1 (5, 11), NALP5/
MATER may have a role also as an ovarian autoantigen.
However, the association of NALP5/MATER autoanti-
bodies (NALP5/MATER-Ab) with hypogonadism cannot
be confirmed in APS1 sera because 85%–90% of patients
with APS1 have hypoparathyroidism, which makes it
problematic to discriminate a NALP5/MATER-specific
ovarian autoimmunity, independently from parathyroid
autoimmunity.
Approximately 1% of women from the general popu-
lation develop primary ovarian insufficiency (POI), as de-
fined by hypergonadotrophic hypogonadism with hypo-
estrogenism and infertility before the age of 40 years (22,
23). The large majority of POI cases remains idiopathic in
nature, but biochemical signs of ovarian autoimmunity
canbedetected in approximately4%–5%ofpatients (24–
26).AutoimmunePOI is almost invariablyassociatedwith
clinical or preclinical AAD and affected women are typi-
cally positive for autoantibodies directed against steroid-
ogenic cytochromeP450enzymes, suchas21-hydroxylase
(21OHAb), 17-hydroxylase (17OHAb), and side-chain
cleavage enzyme (P450sccAb) (steroidogenic enzymes au-
toantibodies, StE-Abs) (24–26). Presence of these auto-
antibodies identifies POI due to autoimmunity to steroid-
producing cells (SCA-POI) (26). Other potential ovarian
autoantigens have been proposed as target of human au-
toantibodies associated with POI, including LH receptor
(27), FSH receptor (28), and zona pellucida proteins (29),
but to date no reliable and reproducible immunoassay has
been developed for any of these markers.
Little is known of the molecular mechanisms respon-
sible for autoimmune-mediated ovarian autoimmunity.
Nevertheless, some studies have shed light on the patho-
physiology of human SCA-POI. Human ovarian autoim-
munity is responsible for a selective mononuclear cell in-
filtration of large, antral follicles (24) and for the selective
autoimmune destruction of theca cells with concomitant
preservationof granulosa cells. For several years after clin-
ical diagnosis of SCA-POI, granulosa cells remain vital, as
demonstrated by increased serum levels of inhibins, and
the pool of functioning follicles is preserved, as demon-
strated by normal serum concentrations of antimüllerian
hormone (25).
The animal model of neonatal thymectomy has proven
instrumental to unravel the critical role of CD4CD25
regulatory T cells in suppressing autoimmune processes
(among which is oophoritis) in regional lymph nodes un-
der a continuous stimulation by autologous antigens (30).
The autoantigen identified in the animal model of neona-
tal thymectomy is the ooplasm-specificMater protein (31,
32). Given that humanNALP5/MATER is ortholog to the
murine autoantigenMater, studies are warranted to eval-
uate the possible role of NALP5/MATER in human ovar-
ian autoimmunity.
In the present study, we have analyzed the frequency of
NALP5/MATER-Abs in a large group of patients with
APS1, AAD with or without gonadic dysfunction, or id-
iopathic POI. In addition, we evaluated the frequency of
autoantibodies against inhibin chains in women with
SCA-POI and in women with idiopathic POI.
Subjects and Methods
Subjects
The study design included serum samples from the following
patients: 1) 172 patients with AAD, 2) 41womenwith AADand
SCA-POI,3)119womenwith idiopathicPOI,4)19patientswith
APS1, and 5) 211 healthy control subjects (Table 1).
The 172 AAD patients (median age 45 y, range 18–70 y, 60
males and 112 females without POI, time from diagnosis: me-
dian 6 y, range 0–45 y) were consecutively recruited by the
ItalianAddisonNetworkbetweenApril 1998and January2014.
The etiological classification of primary adrenal insufficiency
was made according to a diagnostic flow chart that took in con-
sideration the biochemical and imaging data (33), and AADwas
defined by the presence of 21OHAb. None of the AAD patients
had hypogonadism, hypocalcemia, or hypoparathyroidism, and
none was suffering from chronic candidiasis. APS type 2 was
diagnosed in 103 of 172 AAD patients (60%). Among the 112
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females with AAD but with no clinical signs of POI, 11 (10%)
were positive for 17OHAb and 16 (14%) were positive for
P450sccAb. Among the 60 males with AAD, 17OHAb and
P450sccAb were, respectively, found in four (7%) and in five
(8%) subjects.
Among the women with POI (all with 46,XX karyotype and
negative for fragile X mental retardation 1, mutations, or per-
mutations), identified by the onset of clinical and biochemical
signs of hypergonadotrophic hypogonadismbefore the age of 40
years, 41 were positive for StE-Abs and were diagnosed with
SCA-POI. One hundred nineteen womenwith POI, but negative
for StE-Abs, formed group 3 (idiopathic POI). Menarche oc-
curred between 10 and 13 years of age in both SCA-POI and
idiopathic POI patients and blood sampling for the present study
was taken 0–19 years (median 6 y) after the diagnosis of SCA-
POI and 0–9 years (median 3 y) after the diagnosis of idiopathic
POI. All women with SCA-POI had clinical AAD and were
treated with substitutive doses of cortisone acetate and fludro-
cortisone. Twenty-six of the 41 patients with SCA-POI (63%)
were affected by other autoimmune diseases, including thyroid
autoimmune diseases, type 1 diabetes mellitus, vitiligo, chronic
atrophic gastritis, and rheumatoid arthritis. None of the women
with SCA-POI suffered fromhypocalcemia or hypoparathyroid-
ism. All 41 women with SCA-POI were positive for 21OHAb,
whereas 24 women were positive for 17OHAb and 32 were
positive for P450sccAb. Of the 119womenwith idiopathic POI,
12 had documented autoimmune diseases, including thyroid au-
toimmunediseases (n9), type1diabetesmellitus (n1), celiac
disease (n  1), or systemic lupus erythematosus (n  1).
The 19 APS1 patients (median age 23 y, range 5–40 y, nine
males, and 10 females, five of whom suffering from SCA-POI)
enrolled in the study represented the entire population of APS1
subjects recruited by the Italian Addison Network in the period
April 1998 through January 2014. Sixteen of the 19 APS1 pa-
tients (84%) suffered from hypoparathyroidism.
Serum samples from211 Italian healthy control subjects (me-
dian age42y, range18–56y, 102males, and109 females) served
as the control group to determine the upper level of normal in the
NALP5/MATER-Ab assay.
The study was approved by the local Ethics Committee in the
Umbria Region. All patients gave their written informed consent
to be enrolled in the study.
NALP5/MATER and inhibin chain cDNA
A cDNA clone encoding for a truncated version of 1181
amino acids of human NALP5/MATER (catalog number
SC306608; Origene Technologies) was initially used to produce
the radiolabeled autoantigen. The deduced sequence of the pro-
tein produced by this clone is missing a 19-amino acid sequence,
corresponding to region 207–226 of the full-length protein. In a
separate set of experiments, full-length NALP5/MATER (cata-
log number SC318548; Origene Technologies) was also used.
The 35S-radiolabeled NALP5/MATER was produced by cou-
pled in vitro transcription and translation by using rabbit reticu-
locyte lysate (Promega Co) and 35S-methionine (NEN Life Sci-
ence Products, Inc) according to themanufacturer’s instructions.
The full-length cDNA clone for human inhibin- (catalog
number 4126990; Open Biosystems) was subcloned into the
pGEM vector (Easy vector system, catalog numberA1380; Pro-
mega Co) and the 3H-leucine radiolabeled antigen produced as
above.
The full length cDNA clone for human inhibin-A (catalog
number 42699832; Open Biosystems) was used to produce the
35S-methionine radiolabeled antigen.
Development of radiobinding assays for NALP5/
MATER autoantibodies and inhibin chain
autoantibodies
In the autoantibody assays, 20 000 counts per minute (cpm)
of 35S-NALP5/MATERor3H-inhibin-or 35S-inhibin-Awas
immunoprecipitated in duplicatewithhuman serumat adilution
of 1:25. The immunocomplexes were separated in 96-multiwell
plates (Multiscreen; Millipore) by using Protein A-Sepharose
(Pharmacia Biotech) according to the procedures described for
the 65-kDa isoform of glutamic acid decarboxylase autoanti-
bodies (34) and 21OHAbs (6). Finally, immunoprecipitated ra-
dioactivity was evaluated in a microplate scintillation counter
(Top Count-NXT; Packard Bioscience Co). To calculate auto-
antibody levels, a positive standard serumand twonegative stan-
dard sera were used. Levels of autoantibodies were expressed as
a relative index according to the following formula: (cpm sam-
ple  mean cpm negative controls)/(cpm positive controls 
mean cpm negative controls). The upper level of normal was
estimated as the mean 3 SD of the indices observed in healthy
controls. In theNALP5/MATER-Abassay, the positive standard
serum was a serum from an APS1 patient, and the two negative
Table 1. Characteristics of the Subjects Included in the Study
Subject Groups n
Age at Blood
Sampling, y Males/Females
Associated Autoimmune
Diseases, %a 21OHAb 17OHAb P450sccAb
AAD 172 45
(18–70)
60/112 103/172
(60%)
172/172
(100%)
15/172
(9%)
21/172
(12%)
SCA-POI 41 37
(18–44)
0/41 26/41
(63%)
39/41
(95%)
20/41
(49%)
28/41
(68%)
Idiopathic POI 119 38
(20–45)
0/119 12/119
(10%)
0/119 0/119 0/119
APS1 19 23
(5–40)
9/10 19/19
(100%)
17/19
(89%)
13/19
(68%)
15/19
(79%)
Healthy controls 211 42
(18–56)
102/109 0/211 0/211 0/211 0/211
a Autoimmune diseases listed in the text.
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standard sera were obtained from two healthy persons with no
biochemical or clinical signs of autoimmune or other chronic
diseases.
Antisera for inhibin- and inhibin- (00003623 and
H00003625-A01;Abnova)were used as positive controls for the
inhibin autoantibody assays.
Statistical analysis
Differences in autoantibody frequency were analyzed by us-
ing the2 test,withYates’ correctionwhennecessary, or byusing
the Fisher exact test, in 2  5 and 2  2 contingency tables.
Differences in antibody levelswere analyzed by aKruskal-Wallis
test followed by post hoc pairwise comparisons with Bonferroni
correction. Statistical analyses, including complex sample anal-
ysis, were performed using IBM-SPSS version 22.0 (IBM Corp,
2013). P  .05 was considered significant in all tests.
Results
The immunoreactivity of the 35S-NALP5/MATER pro-
duced by in vitro transcription and translation was tested
by using the serum from an APS1 patient with hypopara-
thyroidism. When 20 000 cpm of 35S-NALP5/MATER
was used, 33.4% 	 7.3% of the tracer was immunopre-
cipitated by the positive control serum as compared with
1.0% 	 0.2% immunoprecipitation obtained with the
two negative control sera.
In 211 healthy controls, the mean	 SD of the NALP5/
MATER index was 0.008	 0.009, and the upper level of
normal was set at 0.035. Only 1 of 102 healthy control
male sera, and 0 of 109 healthy control female sera, was
associated with a NALP5/MATER index higher than the
upper level of normal (NALP5/MATER index 0.125).
When a NALP5/MATER index cutoff value of 0.035
was applied, 11 of 19 sera fromAPS1 patients (58%)were
positive for NALP5/MATER-Ab (Figure 1) (median
NALP5/MATER index 0.769, range 0.042–1.17). On the
other hand, 12 of 172 AAD sera (7%) (median NALP5/
MATER index 0.042, range 0.036–1.102), 5 of 41 SCA-
POI sera (12%) (median NALP5/MATER index 0.049,
range 0.037–0.511), and 0 of 119 idiopathic POI sera
were positive for NALP5/MATER-Ab (Figure 1). To con-
firm these results, all weakly positive samples (NALP5/
MATER index  0.05) and an equal number of negative
samples were blindly reanalyzed by another laboratory
participating in the study: concordance among the two
laboratories was 100% for both positive and negative
samples.
The overall contingency table (five groups, subdivided
according to sex) documented that the differences in au-
toantibody frequencies among the five groups of patients
were statistically different (P  .001). When 2  2 con-
tingency tables were applied (Table 2), APS1 patients dif-
fered statistically from every other group both among
males (P .024 vs AADandP .001 vs healthy controls)
and among females (P  .001), AAD females and SCA-
POI patients differed statistically from idiopathic POI
women (P .017 and P .001, respectively), AADmales
differed statistically from healthy control subjects (P 
.049), and SCA-POI patients differed statistically from
healthy control females (P .001), whereas no statistical
difference was observed between AAD females and SCA-
POI or between idiopathic POI and healthy control
subjects.
To exclude that the results might have been influenced
by the use of a truncated version of the autoantigen, all
sera were reanalyzed using full-length NALP5. Similarly
to what observed when using the truncated version of
NALP5, 11 of 19 sera from APS1 patients (58%), 12
of 172 AAD sera (12%), 5 of 41 SCA-POI sera (12%), 0
of 119 idiopathic POI sera, and 1 of 211 healthy control
sera resulted positive for NALP5/MATER-Ab with a
100% agreement between the two constructs.
In APS1 sera, the presence of NALP5/MATER-Ab was
strongly associated with hypoparathyroidism because all
positive samples were from patients affected by this dis-
ease. More specifically, 11 of 16 patients with hypopara-
thyroidism (69%) were positive for NALP5/MATER-Ab.
Among women with APS1 and POI, four of five (80%)
were positive for NALP5/MATER-Ab, but all those sub-
jects were also suffering from hypoparathyroidism.
Figure 1. NALP5/MATER-Ab levels in patients with APS1, AAD, SCA-
POI, and idiopathic POI (iPOI) and in healthy control subjects (HC).
Dotted line shows the upper level of normal of the assay. Filled circles,
female subjects; open circles, male subjects.
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Of the 12 AAD patients positive for NALP5/MATER-
Ab, five were males and seven were females. Four of these
12 patients had isolated AAD with no other sign of an-
other autoimmune or immunomediated disease. Of the
eight AAD patients positive for NALP5/MATER-Abwith
other autoimmune diseases, two had type 1 diabetes mel-
litus, four had Hashimoto’s thyroiditis, four had vitiligo,
and two had atrophic gastritis. The frequencies of con-
comitant autoimmune diseases were not statistically dif-
ferent from those observed among AAD patients negative
for NALP5/MATER-Ab.
None of the 12 AAD patients positive for NALP5/MA-
TER-Abs was positive for either 17OHAb or P450sccAb.
Similarly, no statistical significant association was seen
between the presence of NALP5/MATER-Ab and
17OHAb or P450sccAb in APS1 patients or in SCA-POI
patients.
In NALP5/MATER-Ab-positive female patients, the
index values were significantly higher for APS1 (median
0.123, range 0.06–1.17) than AAD (median 0.045, range
0.036–1.102) (P  .05) and SCA-POI (median 0.048,
range 0.036–0.511) (P .03) subjects. The difference in
index values between the four NALP5/MATER-Ab-pos-
itive APS1 males (median 0.459, range 0.042–1.02) and
the five Ab-positive AAD males (median 0.037, range
0.036–0.529) did not reach a statistical significance.
None of 211 healthy control sera and none of 160 sera
from women with POI, including 41 sera from women
with SCA-POI and 119 sera with idiopathic POI, had an
inhibin- autoantibody index or an inhibin-A autoanti-
body index higher than the upper level of normal of each
assay.
Discussion
POI shows variable clinical manifestations with intermit-
tent ovarian function and even occasional conception af-
ter diagnosis, suggesting a progressive decline of ovarian
function (22, 23). Although clinical and biological fea-
tures of ovarian insufficiency have been well character-
ized, the etiology of the disease remains unclear in most
cases. An autoimmune origin has been proposed to ex-
plain up to 30% of cases of POI (35), but a more accurate
estimate indicates that an ovarian autoimmune reaction
could be unequivocally documented in no more than
4%–5% of women with ovarian insufficiency, more spe-
cifically in association with adrenal autoimmunity
(24–26).
A limited number of translational models for autoim-
mune POI has beenmade available so far. Ovarian failure
due to autoimmune destruction of the ovary can be in-
duced by immunization with crude or defined ovarian an-
tigens (36) orby thymectomyat day3after birth in various
strainsof inbredmice (30). In this latter3-day thymectomy
model, a 125-kDa oocyte-specific protein, localized in the
cytoplasmof growingoocytes, acts as anautoantigen (32),
andautoantibodies reacting to this proteinhavebeen iden-
tified. This protein was further characterized (21) as a
maternal protein required for early embryonic develop-
ment, the so-calledmaternal antigen that embryo requires
(MATER). Transgenic expression of MATER in antigen-
presenting cells induces antigen-specific tolerance that
mitigates the autoimmune phenomenon at the ovarian
level (31) both in terms of incidence of autoantibodies
production against oocyte proteins and in terms of lym-
phocytic infiltration of the ovary. On the other hand, be-
cause the oophoritis is reduced but not completely sup-
pressed, the contribution of MATER to murine ovarian
autoimmunity is not exclusive, and alternative or concom-
itant pathogenetic targets for T cells may exist.
NALP5, a parathyroid autoantigen in APS1 patients
(20), is the human homolog of murine MATER (21). Be-
cause NALP5 expression is restricted to parathyroid
glands inmen but is extended also to the ovaries inwomen
Table 2. Statistical Analysis (P Values) of the Comparisons of Frequency of NALP5/MATER-Ab in the Studied
Groups
APS1
AAD Without
POI SCA-POI iPOI HC
Females
APS1 .001 .001 .001 .001
AAD without POI NS .017 .023
SCA-POI .001 .001
iPOI NS
Males
AAD without POI .024
SCA-POI — —
iPOI — — —
HC .001 .049 — —
Abbreviations: HC, healthy controls; iPOI, idiopathic POI; NS, Not significant.
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(20), we hypothesized that this protein could act as an
ovarian autoantigen in women affected by POI, and we
performed radiobinding assays in large groups of women
affected by SCA-POI or idiopathic POI to detect NALP5/
MATER-Ab. NALP5/MATER-Ab were present in 58%
patients with APS1, which is in line with the results of
previous investigations (20, 37). However, the results ob-
served in APS1 patients could not be interpreted as a dem-
onstration of an ovary-specific autoreactivity because all
positive sera were from patients affected with hypopara-
thyroidism. Nevertheless, the high frequency of NALP5/
MATER-Ab in APS1 patients is in line with the concept
that autoimmune mechanisms in subjects with mutation
of autoimmune regulator are similar to those observed in
the thymectomy model (38).
Our study demonstrates that three groups of patients
withdifferent autoreactivity toNALP5-MATERexist: pa-
tients with APS1 who show the strongest reactivity, pa-
tients with AAD and SCA-POI who show a less frequent
but still statistically significant reactivity, and, finally, pa-
tients with idiopathic POI and healthy control subjects
who do not exhibit any (or almost any) autoreactivity
at all.
The finding that NALP5/MATER-Ab were detected in
12% of women with SCA-POI could be interpreted as an
indirect sign of an oocyte-directed autoimmune process
occurring in a small subgroup of these patients in con-
comitancewith the autoimmune attack against theca cells.
However, it must be noted that NALP5 ovarian expres-
sion has so far been demonstrated in humans only at the
mRNA level (20) and that AADwomen found positive for
NALP5/MATER-Ab did not show clinical or biochemical
signs of POI. In addition, in AAD patients, occurrence of
NALP5/MATER-Ab was similar in males and in females.
Furthermore, this novel marker of ovarian autoimmunity
waspresent exclusively inwomenwithanongoingadrenal
autoimmune process that confirms that SCA-POI is al-
most invariably associated with clinical or preclinical
AAD. For this reason, presence of 21OHAb remains the
marker at highest diagnostic accuracy for the diagnosis of
autoimmunePOI (24–26).On the other hand, the absence
of NALP5/MATER-Ab in our group of so-called idio-
pathic POI confirms that we cannot yet understand the
true nature of the disease in this group of women.
Interestingly, NALP5/MATER-Ab were detected in
7%patientswithAADwithout hypogonadism.More spe-
cifically, in 4 of 12 positive AAD sera, NALP5/MA-
TER-Ab levels were as high as those typically detected in
patients with APS1, ruling out the possibility that auto-
antibody positivity was the result of an aspecific immu-
noreaction. In addition, the presence of these autoanti-
bodies in only 1 of 211 healthy control sera and their
absence in 119womenwith idiopathic POI strengthen the
conclusion that presence of NALP5/MATER-Ab in 7%
patients with AAD is the expression of a consistent auto-
immune phenomenon. This result is somehow surprising
because the tissue expression pattern of this autoantigen
could not predict its role as a potential autoantigen in
adrenal autoimmunity. The frequent occurrence of other
autoimmune diseases in patients with AAD in the context
of the so-called APS suggests that NALP5/MATER-Ab
may be more likely related to other autoimmune diseases
present in patients with AAD rather than to the adrenal
autoimmune process per se and not necessarily a sign of an
oocyte-directed autoimmune process. Although none of
the tested 172 AAD patients had clinical or biochemical
signs of either hypoparathyroidism or hypogonadism and
frequency of concomitant autoimmune diseases was sim-
ilar in NALP5/MATER-Ab positive and -Ab negative
AAD patients, we cannot exclude that an initial autoim-
mune process against parathyroid or ovary might have
started, thus leading to the production of NALP5/
MATER-Ab. Further studies are needed to address the
question whether NALP5/MATER-Ab may be an early
marker of parathyroid or ovarian autoimmunity in pa-
tients with AAD or a marker of atypical forms of APS1.
NALP5 belongs to a family of cytoplasmic proteins
comprising 14 members that share similar structure and
are involved in apoptosis and inflammation as well as in
reproduction. TheNALP5 gene clusters withNALP 2, 4,
7, 8, 9, 11, 12, and 13 on human chromosome 19q13.4,
reflecting a commonphylogenetic origin thatwell fitswith
the expression patterns in human oocytes and embryos
(39). Notably, NALP13 is closest to NALP5 on the phy-
logenetic tree and has been reported to be expressed in the
ovary. Similarly, also NALP9 has been reported to show
an expression pattern similar to that of NALP5. Although
NALP5 appears to be a strong parathyroid autoantigen in
APS1 patients, the low levels of NALP5/MATER-Ab in
womenwith SCA-POI raises thequestionwhetherovarian
NALP autoimmunitymight be triggered by anothermem-
ber of the NALP family, with partial cross-reactivity to
NALP5. At the moment we cannot resolve this issue, and
further studies are warranted to address this specific
question.
In our search for ovarian autoantibodies, we also in-
cluded inhibins as potential autoantigens. The rationale
for this approachwas provided by an experimental model
of autoimmune oophoritis induced in SWXJ female mice
by immunization with the p215–234 sequence of in-
hibin- (36). To evaluate whether inhibins may be target
of an autoreactive process also in human POI, we devel-
oped RIAs for the detection of autoantibodies against in-
hibin chains in human serum.Although immunoreactivity
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of inhibin-B could not be tested becausewewere not able
to efficiently produce radiolabeled inhibin-B using the in
vitro translation technique, no sample resultedpositive for
inhibin - or inhibin A-Ab, neither in SCA-POI nor in
idiopathic-POI, which suggests that inhibins are not likely
candidate targets of autoantibodies in human autoim-
mune oophoritis.
Here we report that the human MATER homolog,
NALP5, is targeted by an autoimmune process in a small
subgroup of women with SCA-POI. The involvement of
several different target antigens in ovarian autoimmunity
may reflect a variety of pathological mechanisms whose
clinical and diagnostic relevance still needs to be
investigated.
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